Aprea Therapeutics, Inc. (APRE) vs Co-Diagnostics, Inc. (CODX)
A side-by-side comparison of Aprea Therapeutics, Inc. and Co-Diagnostics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APRE
Aprea Therapeutics, Inc.
$0.64HealthcareDelayed quote: Oct 6, 2026, 2:58 PM EDT
CODX
Co-Diagnostics, Inc.
$1.11HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Total return — APRE vs CODX
growth of $100 · dividends reinvested · last 7yAPRE -99.8% (-60.0%/yr)CODX -96.5% (-38.2%/yr)CODX compounded faster over this window
Log scale — wide-divergence pair
APRE CODX
APRE vs CODX: by the numbers
- •APRE is the larger company ($8M vs $7M market cap).
- •Both run net losses; APRE's is the smaller (0.00% vs -6523.04% net margin).
Metrics side by side
Valuation
| Metric | APRE | CODX |
|---|---|---|
| P/S ratio | N/A | 9.62 |
| P/B ratio | 0.20 | 0.55 |
Profitability
| Metric | APRE | CODX |
|---|---|---|
| Gross margin | 0.00% | 64.28% |
| Operating margin | 0.00% | -5025.53% |
| Net margin | 0.00% | -6523.04% |
| ROE | -31.99% | -370.16% |
| ROIC | -33.73% | -219.15% |
Growth (annualized)
| Metric | APRE | CODX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -62.43% |
| Total return CAGR (5Y) | -63.30% | -66.53% |
Frequently asked
- How have APRE and CODX total returns compared?
- Over the past 5 years, APRE delivered -63.30% and CODX delivered -66.53% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.